New Breakthroughs to Avoid Shortage of Treatment for Those with Inherited COPD
Mr. Jeffrey Davis, COO of PlasmaTech BioPharmaceuticals, a Dallas & New York-based biopharmaceutical company focused on advancing targeted treatments for significant unmet needs of critical patient care joins eHealth Radio and the Pharamceutical, Health Care & News Channels.
Listen to interview with host Eric Michaels & guest Mr. Jeffrey Davis discuss the following:
What is Inherited COPD? Who does it affect?
Why does the World Health Organization and the American Thoracic Society recommend that every individual diagnosed with COPD be tested for Alpha-1?
How do these patients get the Alpha-1 Anti-trypsin that they need?
Why could we see a shortage of this drug in a few years?
How can your Company’s technology change that?
What resources are available for those with Inherited COPD?
About PlasmaTech Biopharmaceuticals, Inc. PlasmaTech Biopharmaceuticals, Inc. (PlasmaTech) is a biopharmaceutical company focused on advancing targeted treatments for significant unmet needs of critical patient care. Exploiting two distinct proprietary platforms, Salt Diafiltration (SDF™) Process and Polymer Hydrogel Technology (PHT™), PlasmaTech is active in the development and commercialization of plasma-derived therapeutics and cancer supportive care products. The company has developed a robust product pipeline that includes two commercial stage products, MuGard® and ProctiGard™ as well as multiple pre-clinical follow-on products. For more information visit, www.plasmatechbio.com.
Jeffrey B. Davis holds a B.S. in biomedical engineering from Boston University and an MBA degree from the Wharton School, University of Pennsylvania. Mr. Davis has held a variety of c-level executive positions in the biotechnology industry, and is currently a Director and Chief Operating Officer of PlasmaTech Biopharmaceuticals, Inc.
Mr. Davis was previously CEO of Access Pharmaceuticals, Inc., and has previously served in a variety of senior investment banking and management positions. Mr. Davis was an investment banker with various Deutsche Bank AG banking organizations, both in the U.S. and Europe. Mr. Davis also served in senior marketing and product management positions at AT&T Bell Laboratories, where he was also a member of the technical staff, and at Philips Medical Systems North America.